Zynerba Pharmaceuticals Inc
ZYNE
Get informed when a big investor buys or sells
+ FollowMarket Cap$70.12M
Close$
$3.03
132.9% upside
Current Fair Value
132.9% upsideUndervalued by 132.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $70.12 Million |
|---|---|
| Enterprise Value | $34.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.82 |
| Beta | 1.19 |
| Outstanding Shares | 50,150,138 |
Return
| Return on Equity | -127.53% |
|---|---|
| Return on Assets | -91.43% |
| Return on Invested Capital | -133.39% |
Valuation & Multiples
| P/E Ratio | -1.59 |
|---|---|
| PEG | -70.28 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.89 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zynerba Pharmaceuticals Inc
CEO: Armando Anido